The SRNE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SRNE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SRNE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View SRNE Detailed Price Forecast - CNN Money||View SRNE Detailed Summary - Google Finance|
|View SRNE Detailed Summary - Yahoo! Finance||View SRNE Stock Research & Analysis - Zacks.com|
|View SRNE Trends & Analysis - Trade-Ideas||View SRNE Major Holders - Barrons|
|View SRNE Call Transcripts - NASDAQ||View SRNE Breaking News & Analysis - Seeking Alpha|
|View SRNE Annual Report - CompanySpotlight.com||View SRNE OTC Short Report - OTCShortReport.com|
|View SRNE Fundamentals - TradeKing||View SRNE SEC Filings - Bar Chart|
|View Historical Prices for SRNE - The WSJ||View Performance/Total Return for SRNE - Morningstar|
|View the Analyst Estimates for SRNE - MarketWatch||View the Earnings History for SRNE - CNBC|
|View the SRNE Earnings - StockMarketWatch||View SRNE Buy or Sell Recommendations - MacroAxis|
|View the SRNE Bullish Patterns - American Bulls||View SRNE Short Pain Metrics - ShortPainBot.com|
|View SRNE Stock Mentions - StockTwits||View SRNE Stock Mentions - PennyStockTweets|
|View SRNE Stock Mentions - Twitter||View SRNE Investment Forum News - Investor Hub|
|View SRNE Stock Mentions - Yahoo! Message Board||View SRNE Stock Mentions - Seeking Alpha|
|View Insider Transactions for SRNE - SECform4.com||View Insider Transactions for SRNE - Insider Cow|
|View SRNE Major Holdings Summary - CNBC||View Insider Disclosure for SRNE - OTC Markets|
|View Insider Transactions for SRNE - Yahoo! Finance||View Institutional Holdings for SRNE - NASDAQ|
|View SRNE Stock Insight & Charts - FinViz.com||View SRNE Investment Charts - StockCharts.com|
|View SRNE Stock Overview & Charts - BarChart||View SRNE User Generated Charts - Trading View|
Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million
Posted on Thursday November 08, 2018
Sorrento Therapeutics, Inc. (SRNE), a clinical-stage immunotherapy biotech company, announces the closing of a debt financing for up to $150 million. The financing is being provided by funds and accounts managed by Oaktree Capital Management, L.P. (“Oaktree”), a leading global investment firm.
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
Posted on Tuesday November 06, 2018
Sorrento Therapeutics, Inc. (SRNE) ("Sorrento") announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life Sciences. The preliminary data for the Hepatic Immunotherapy for Metastases (HITM-SURE) clinical trial results will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 7-11 in Washington, DC. Five patients, four pancreatic and one colorectal, with carcinoembryonic antigen–positive (CEA+), unresectable stage IV adenocarcinoma with liver metastases, who had failed one or more lines of systemic chemotherapy, each received three hepatic artery infusions of Sorrento autologous anti-CEA CAR-T cells using the Hepatic Immunotherapy for Metastases (HITM) method.
Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
Posted on Thursday November 01, 2018
Sorrento Therapeutics, Inc. (SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to evaluate the safety and efficacy of CD38 CAR-T therapy in relapsed or refractory multiple myeloma patients at two clinical sites – University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island. The CD38 CAR-T cells manufactured at both Sorrento cGMP facilities (San Diego, CA and Providence, RI) met all release specifications and were used in the study. This study is the first US-based clinical trial targeting CD38 using an autologous CAR-T cell therapy.
Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Thursday October 25, 2018
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.